Resources from the same session
3MO - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2
Presenter: Ryan Gentzler
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
5MO - Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study
Presenter: Maria Rosario Garcia Campelo
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Q&A
Session: Mini Oral session 2
Resources:
Webcast
6MO - Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study
Presenter: Natasha Leighl
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
244MO - Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC
Presenter: Federico Cappuzzo
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 6MO and 244MO
Presenter: Hazel O'Sullivan
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 2
Resources:
Webcast